The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
SmithD.C., KalebicT., InfanteJ.R.Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs.2015; 33(3): 652–663.
2.
RichardsonP.G., BazR., WangM.Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood.2014; 124(7): 1038–1046.
GuptaN., SalehM., VenkatakrishnanK.Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: Population pharmacokinetic (PK) analysis of pooled data from 4 phase-1 studies. Blood2011; 118(21): (abstract 1433). http://www.bloodjournal.org/content/118/21/1433. Accessed February 6, 2016.
5.
GuptaN., GohY.T., MinC.K.Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: A phase 1 study. J Hematol Oncol.2015; 103(8): 1–9.
6.
MerliniG., SanchorawalaV., ZonderJ.A.MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): Results of a phase 1 study. Blood.2012; 120(21): (abstract 731). http://www.bloodjournal.org/content/120/21/731. Accessed February 5, 2016.
7.
KumarS., BensingerW.I., ReederC.B.Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: Results from a phase 1 dose-escalation study. Blood.2011; 118(21): (abstract 816). http://www.bloodjournal.org/content/118/21/816. Accessed February 4, 2016.
8.
GuptaN., VenkatakrishnanK., NoeD.A.A drug-drug interaction between strong CYP3A4 inhibitor ketoconazole and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol.2013; 31(suppl): (abstract 2555). http://meetinglibrary.asco.org/print/1155866. Accessed February 5, 2016.
9.
GuptaN., HanleyM.J., VenkatakrishnanK.A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors. Mol Cancer Ther.2015; 14(12 suppl 2): (abstract B147). http://mct.accrjournals.org/content/14/12_Supple-ment_2/B147.short. Accessed February 5, 2016.
10.
KumarS.K., BerdejaJ.G., NiesvizkyR.Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study. Lancet Oncol.2014; 15(13): 1503–1512.
11.
MoreauP., MassziT., GrzaskoN.Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): The phase 3 Tourmaline- MM1 study (NCT01564537). Blood.2015; 126(23): (abstract 727). http://www.bloodjournal.org/content/126/23/727.full.pdf. Accessed January 13, 2016.
12.
KumarS.K., BensingerW.I., ZimmermanT.M.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood.2014; 124(7): 1047–1055.
13.
KuenenB., WitteveenP.O., RuijterR.A phase 1 pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res.2010; 16(6): 1915–1923.
14.
Portrazza [package insert].Indianapolis, IN: Eli Lilly and Company; 2015.
ThatcherN., HirschF.R., LuftA.V.Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol.2015; 16(7): 763–774.
17.
KumarS.K., LaplantB., RoyV.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J.2015; 5: e338. http://www.nature.com/bcj/journal/v4/n8/full/bcj201560a.html. Accessed January 13, 2016.
18.
Paz-AresL., MezgerJ., CiuleanuT.E.Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): An open-label, randomized, controlled phase 3 study. Lancet Oncol.2015; 16(3): 328–337. ■
